
WHAT IS CLAIMED IS:

1. A process for preparing a solid dispersion, comprising:

(a) dissolving in a suitable solvent (i) an active pharmaceutical ingredient (API) comprising a compound of Formula I



I

where:

R^0 is halo;

R^1 and R^2 are H or are independently methyl or methoxy;

R^3 and R^4 are independently methyl or methoxy if R^1 and R^2 are H, or are H if R^1 and R^2 are independently methyl or methoxy;

A^1 and A^2 are each independently CH or N;

R^5 is C $_{1-4}$ alkyl or haloalkyl, C_{1-4} alkylsulfonyl or haloalkylsulfonyl, halo, nitro or cyano;

X is -O- or -NH-;

Y is $-(CH_2)_n-$ where n is 0, 1, 2 or 3; and

R^6 is an unsubstituted or substituted 3- to 7-membered carbocyclic or heterocyclic ring as defined herein, or is NR^7R^8;

wherein, if R^6 is NR^7R^8, R^7 and R^8 are each independently H or $R^9-(CH_2)_m-$ groups, no more than one of R^7 and R^8 being H, where each R^9 is independently a 3- to 7-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z^1 groups as defined below, and each m is independently 0 or 1 ; and

wherein, if R^6 is a substituted carbocyclic or heterocyclic ring, substituents thereon are no more than two Z^1 groups and/or no more than one Z^2 group, Z^1 groups being independently selected from (a) C_{1-4} alkyl, C_{2-4} alkenyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkylamino, C_{1-4} alkylsulfonyl, C_{1-4} alkylsulfonylamino, C_{1-4} alkylcarbonyl, C_{1-4} alkylcarbonylamino and C_{1-4} alkylcarboxy, each optionally substituted with one or more substituents independently selected from halo, hydroxy, C $_{1-4}$ alkoxy, amino, C_{1-4} alkylamino, di-(C_{1-4} alkyl)amino and cyano, (b) halo, (e) hydroxy, (f) amino and

(g) oxo groups, and Z^2 being (i) a further 3- to 6-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z^1 groups as defined above, or (ii) NR^7R^8 where R^7 and R^8 are as defined above;

or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable water-soluble polymeric carrier and (iii) at least one pharmaceutically acceptable surfactant; and

(b) removing the solvent to provide a solid matrix comprising the at least one polymeric carrier and the at least one surfactant and having the compound or a salt thereof dispersed in an essentially non-crystalline form therein.

2. The process of Claim 1, wherein the API comprises a compound of Formula I in parent-compound form; and the process further comprises adding a pharmaceutically acceptable acid before removing the solvent.

3. The process of Claim 1, wherein the solvent is removed under heat and/or vacuum.

4. The process of Claim 1, wherein the solvent is removed by rotary evaporation or by spray-drying.

5. The process of Claim 1, wherein the solvent comprises one or more of methanol, ethanol, acetone, tetrahydrofuran and dichloromethane.

6. The process of Claim 1, wherein the solvent comprises a dichloromethane/methanol or THF/water mixture.

7. The process of Claim 1, wherein no more than about 5% of the compound of Formula I in the solid matrix is crystalline as observed by X-ray diffraction analysis.

8. The process of Claim 1, wherein no more than about 2% of the compound of Formula I in the solid matrix is crystalline as observed by X-ray diffraction analysis.

9. The process of Claim 1, wherein no more than about 1% of the compound of Formula I in the solid matrix is crystalline as observed by X-ray diffraction analysis.

10. The process of Claim 1, wherein API is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5- y loxy)benzamide.

11. The process of claim 10, wherein the polymeric carrier is a copovidone.

12. The process of Claim 11, wherein the surfactant is a polysorbate.